Seletracetam (Ucb 44212) is an analog of the antiepileptic agent Levetiracetam. Seletracetam is a small molecule SV2A modulator for the research of epilepsy^[1][2][3]. IC50 & Target: SV2A^[1] In Vitro: Seletracetam decreases seizure activity in a number of epilepsy models and binds to the synaptic vesicle protein SV2A^[2].
Seletracetam decreases synaptic responses in a time-, frequency- and concentration-dependent manner^[2].
Seletracetam modifies rates of presynaptic release^[2].
Seletracetam inhibits high-voltage-activated Ca2⁺ currents and intracellular Ca2⁺ increase in rat cortical neurons in vitro^[2].